Monday Moves [12/17/2012]
New Worldwide President at Depuy Synthes. BSD Medical Appoints CFO. Three new representatives elected to the SLAS board of directors.
Max Reinhardt Named Worldwide President of Depuy Synthes Spine
The DePuy Synthes Companies of Johnson & Johnson has announced that Max Reinhardt has been named worldwide president of DePuy Synthes Spine. Reinhardt has been with the company since 2002, most recently as vice president of worldwide marketing. Reinhardt began his career with DePuy Spine in 2002 as director of sales and marketing in the UK. Four years later he became vice president of sales in the U.S., and in early 2011, was named vice president of worldwide marketing. In 2012, when Johnson & Johnson completed its acquisition of Synthes Inc., Reinhardt was charged with helping to integrate the global spine divisions of both companies into DePuy Synthes Spine. [DePuy Synthes
BSD Medical Appoints William Barth as Chief Financial Officer
BUSINESS WIRE - BSD Medical Corporation. a provider of medical systems that utilize heat therapy to treat cancer, has announced the appointment of William S. Barth as chief financial officer and corporate secretary. Barth commenced his employment with the company on December 10, 2012, and will assume the duties of effective January 1, 2013, upon the departure of Dennis Gauger, current chief financial officer and corporate secretary. Barth has an extensive history as CFO for both publicly and privately held companies in the medical device and biotechnology industries. Since May 2011 he has served as an independent corporate financial and strategic planning consultant. From June 2008 to May 2011 he served as senior VP and CFO for Emphusion LLC, a private-equity-owned Contract Research Organization (CRO) providing data management and bio statistical analysis services for new drug and medical device development. [BSD Medical
Three New Representatives Elected to the SLAS Board of Directors
Members of the Society for Laboratory Automation and Screening (SLAS) elected three new representatives to serve on the SLAS board of directors for three-year terms effective January 1, 2013. Josh Bittker is currently the director of lead discovery in the Chemical Biology Platform at the Broad Institute of MIT and Harvard, where he is responsible for the HTS, automation, analytical chemistry, and compound management groups. Richard Ellson, is a founder of Labcyte where he serves as chief technical officer and works on acoustic liquid handling and automation technologies. As an SLAS member, he has gained broad and long-term perspective through many roles with the organization and its journals. Finally, Dr. Dean Ho is currently a professor in the Division of Oral Biology and Medicine, the Division of Advanced Prosthodontics, Biomaterials, and Hospital Dentistry, and co-director of the Weintraub Center for Reconstructive Biotechnology at the UCLA School of Dentistry. [SLAS